Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
224 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (1221)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (13)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (18)
  • Bone & Muscle (10)
  • Cancer (102)
    • Brain Cancer (3)
    • Breast Cancer (13)
    • Gastrointestinal (2)
    • Gynecologic Cancer (30)
    • Kidney Cancer (1)
    • Leukemia (9)
    • Liver Cancer (2)
    • Lung Cancer (4)
    • Lymphoma (10)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (2)
    • Prostate Cancer (3)
    • Sarcoma (2)
    • Skin Cancer (2)
      • (-) Melanoma (2)
    • Solid Tumors (4)
  • Child Development (4)
  • COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (12)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (26)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (187)
  • Heart Disease (130)
  • Infectious Disease (48)
  • Insomnia (3)
  • Kidney Disease (12)
  • Liver Disease (52)
  • Lung Disease (31)
  • (-) Meniere's Disease (1)
  • Neurological Disorders (126)
  • Nutrition (5)
  • Obesity (9)
  • Obstetrics & Gynecology (55)
  • Pain Management (1)
  • Pediatrics (98)
  • Psychiatric Disorders (67)
  • Rehabilitation (9)
  • Stroke (7)
  • Surgery (7)
  • Transplant (45)
  • Urology (3)
  • Vascular Conditions (10)
Displaying 1 - 3 of 3

Study of Nivolumab in Patients with Resected Stage IIB/IIC Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Read More

Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Read More

A study for subjects with Unilateral Menieres disease using corticosteroid (OTO-104)

Condition: Meniere's Disease
Investigator: Anil Lalwani, MD
Status: Closed
Meniere's Disease is an inner ear disorder that causes episodes of vertigo. The purpose of this study is to test the effectiveness and safety of OTO-104 compared to placebo in subjects with Menieres disease. OTO-104 contains an active ingredient, called dexamethasone, which is a commonly used corticosteroid that has been prescribed by doctors for…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science